



# Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Cancer

---

<b>State(s):</b> <input checked="" type="checkbox"/> Idaho <input checked="" type="checkbox"/> Montana <input checked="" type="checkbox"/> Oregon <input checked="" type="checkbox"/> Washington <input type="checkbox"/> Other:	<b>LOB(s):</b> <input checked="" type="checkbox"/> Commercial <input checked="" type="checkbox"/> Medicare <input checked="" type="checkbox"/> Medicaid
---	--

## Enterprise Policy

---

*Clinical Guidelines are written when necessary to provide guidance to providers and members in order to outline and clarify coverage criteria in accordance with the terms of the Member's policy. This Clinical Guideline only applies to PacificSource Health Plans, PacificSource Community Health Plans, and PacificSource Community Solutions in Idaho, Montana, Oregon, and Washington. Because of the changing nature of medicine, this list is subject to revision and update without notice. This document is designed for informational purposes only and is not an authorization or contract. Coverage determination are made on a case-by-case basis and subject to the terms, conditions, limitations, and exclusions of the Member's policy. Member policies differ in benefits and to the extent a conflict exists between the Clinical Guideline and the Member's policy, the Member's policy language shall control. Clinical Guidelines do not constitute medical advice nor guarantee coverage.*

## Background

---

Hyperthermic Intraperitoneal Chemotherapy (HIPEC) also known as Intraperitoneal Hyperthermic Chemotherapy (IPHC) is a highly concentrated, heated chemotherapy treatment delivered directly to the abdomen during surgery. HIPEC is used as an adjunct to surgery for the treatment of gastrointestinal, appendiceal, ovarian, or mesothelial cancers that have metastasized or may metastasize into the peritoneal cavity. Chemotherapy drugs are introduced directly into the peritoneal space to eliminate microscopic tumors on the peritoneal lining and/or outer surfaces of affected organs to eliminate tumor cells that have disseminated.

## Criteria

---

### Commercial

#### **Prior authorization is required.**

PacificSource considers Hyperthermic Intraperitoneal Chemotherapy (HIPEC) medically necessary when used at time of or after cytoreductive (debulking) surgery for any of the following:

- Malignant peritoneal mesothelioma with metastasis limited to the abdominal cavity;
- Peritoneal carcinomatosis from gastric cancer (ie., Appendix, Colon, Rectal, Pancreatic and Gastric Cancers) without extra-abdominal metastases;
- Pseudomyxoma Peritonei (PMP); or
- Stage II or Stage III epithelial ovarian cancer.

## Medicaid

PacificSource Community Solutions follows Oregon Health Plan (OHP) per Oregon Administrative Rules (OAR) 410-141-3820 to 3830 for coverage of Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Cancer.

## Medicare

PacificSource Medicare follows National Coverage Determination (NCD) 110.1 Hyperthermia for treatment of cancer.

## Experimental/Investigational/Unproven

---

PacificSource considers Hyperthermic Intraperitoneal Chemotherapy (HIPEC) to be experimental, investigational or unproven for any other indications because its effectiveness has not been proven.

PacificSource considers Whole Body Hyperthermia (CPT 77605) to be experimental, investigational or unproven for any indication.

## Coding Information

---

The following list of codes are for informational purposes only and may not be all-inclusive. Deleted codes and codes which are not effective at the time the service is rendered may not be eligible for reimbursement.

77600 Hyperthermia, Externally Generated; Superficial

77610 Hyperthermia Generated, Interstitial Probe(S); Up To 5 Interstitial Applicators

77615 Hyperthermia Generated, Interstitial Probe(S); > 5 Interstitial Applicators

77620 Hyperthermia Generated, Intracavitary Probe(S)

96446 Chemotherapy administration into the peritoneal cavity via indwelling port or catheter

96549 Unlisted chemotherapy procedure

Not Covered Code

77605 Hyperthermia, Externally Generated; Deep

CPT® codes, descriptions and materials are copyrighted by the American Medical Association (AMA).

## Definitions

---

**Appendiceal Cancer** - rare form of cancer (e.g., Neuroendocrine tumor, Appendiceal mucocoeles, Colonic-type adenocarcinoma, Signet-ring cell adenocarcinoma and Goblet cell

carcinomas/Adenoneuroendocrines) that initially develop as tumors in the appendix and can potentially spread into to the abdominal cavity.

**Malignant Peritoneal Mesothelioma** - a rare, highly lethal malignancy of the serosal membranes of the pleura, peritoneum, pericardium, or tunica vaginalis testes. The peritoneum is the second most frequent site of origin of mesothelioma, following the pleura. The pathogenesis of all forms of mesothelioma is strongly associated with industrial pollutants, of which asbestos is the principal carcinogen associated with the disease.

**Pseudomyxoma Peritonei (PMP)** - progressive accumulation of mucus-secreting (mucinous) tumor cells within the abdomen and pelvis. The most common sites of origin of the tumor are the appendix and ovary. The degree of malignant potential is variable; about 50% of patients live 5 years. Seventy-five percent of patients with PMP are women between 45 and 75 years of age.

**Stage III Ovarian Cancer** - cancer in one or both ovaries and has either spread beyond the pelvis to the lining of the abdomen or to the lymph nodes in the back of the abdomen.

## References

---

Cardis, M. et al. Cytoreduction and HIPEC in the treatment of “unconventional” secondary peritoneal carcinomatosis. *World J Surg Oncol*. 2015; 13: 305. Accessed 10/12/2017, 9/24/2018, 9/5/2019, 6/30/2020. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4618525/>

Cummins, K. A. et al. Peritoneal dissemination from high-grade appendiceal cancer treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). *Gastrointest Oncol* 2016; 7(1):3-9. Accessed 10/12/2017, 9/24/2018, 9/5/2019, 6/30/2020. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4754307/pdf/jgo-07-01-003.pdf>

Dubé, P. et al. Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Cancer. *Curr Oncol*. 2015 Apr; 22(2): e100–e112. Accessed 10/12/2017, 9/24/2018, 9/5/2019, 6/30/2020. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4399618/>

Hayes Health Technology Assessment Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis resulting from Ovarian Cancer, Winifred S. Hayes, Inc., 8/26/2019.

Hayes Health Technology Assessment Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis resulting from Peritoneal Mesothelioma, Winifred S. Hayes, Inc., 11/5/2019

Levine, EA et al. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Surface Malignancy: Experience with 1,000 Patients. *J Am Coll Surg*. 2014 Apr; 218(4): 573–585. Accessed 10/12/2017, 9/24/2018, 9/5/2019, 6/30/2020. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3965636/>

Mirnezami, R. et al. Cytoreductive surgery and intraperitoneal chemotherapy for colorectal peritoneal metastases. *World J Gastroenterol*. 2014 Oct 14; 20(38): 14018–14032. Accessed 10/12/2017, 9/24/2018, 9/5/2019, 6/30/2020. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4194588/>

Mirnezami R et al. Cytoreductive surgery in combination with hyperthermic intraperitoneal chemotherapy improves survival in patients with colorectal peritoneal metastases compared with systemic chemotherapy alone. *Br J Cancer*. 2014 Oct 14; 111(8): 1500–1508. Accessed 10/12/2017, 9/24/2018, 9/5/2019, 6/30/2020 <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4200082/>

National Comprehensive Cancer Network (NCCN): Colon Cancer. Version 2.2019.

National Comprehensive Cancer Network (NCCN): Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer. Version 1.2019

Randle, RW et al. Peritoneal surface disease with synchronous hepatic involvement treated with Cytoreductive Surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol. 2015 May; 22(5):1634-8. Accessed 10/12/2017, 9/24/2018, 9/5/2019, 6/30/2020.  
<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4329114/>

Spiliotis JD, et al. Cytoreductive Surgery and HIPEC for Peritoneal Carcinomatosis in the Elderly. Int J Surg Oncol. 2014; 2014: 987475. Accessed 10/12/2017, 9/24/2018, 9/5/2019, 6/30/2020.  
<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4009200/>

## Appendix

---

**Policy Number:**

**Effective:** 7/1/2020

**Next review:** 6/1/2023

**Policy type:** [Enterprise]

**Author(s):**

**Depts:** Health Services

**Applicable regulation(s):**

**Commercial Ops:** 6/2022

**Government Ops:** 6/2022